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ABSTRACT 
One hundred consecutive patients with documented bactéremia and neutrophil count of 0.5x109 /L or
below were retrospectively studied to determine the pattern of infection at the Aga Khan University
Hospital in Karachi. These included patients with primary haematologic malignancies presenting with
low counts, and those patients with cancer who developed neutropenia as a result of chemotherapy. The
gram negative organism pseudomonas aeruginosa was the most common bacterial organism isolated
constituting 31% of all positive blood cultures. Gram positive organisms were frequently isolated
comprising 24% of all isolates of which 15% were Staph.aureus. Staph. epidermidis was not isolated in
this series. Salmonella species were isolated in 9 patients. The other gram negative rods included non-
lactose fermenting organisms frequently isolated in a nosocomial setting including Serratia and
Acinetobacter. Four patients had positive fungal blood cultures. A single positive anaerobic culture was
obtained. Sensitivities of the Pseudomonas aeruginosa reflected the high frequency of resistance seen in
nosocomial isolates and those from the community. More than half (54.8%) of the isolates were
resistant to carbenicillin and 9.6% resistant to gentamicin. Although 3.2% were resistant to cefotaxime,
none were resistant to ofloxacin or ceftazidime reflecting the relatively recent arrival of the latter. In
contrast, 23% of Staph: aureus were still sensitive to penicillin. Methicillin (cloxacillin) resistant Staph.
aureus did not occur. However 26.6% of the Staph. aureus were resistantto erythromycin. Knowledge
of the prevailing pattern of infection permits the development of investigative and therapeutic
approaches of optimal efficacy (JPMA 41: 35, 1991).
INTRODUCTION 
Patients with haematologic and other malignancies are susceptible to infections. Many factors
predispose this patient population to infection including tumor specific deficiencies in host defence
mechanisms due to malignant processes and cytotoxic chemotherapy. Neutropenic patients are most
susceptible to infections caused by gram negative bacilli and gram positive cocci. Candida and
aspergillus1. The spectrum of infection may be further altered by changes in medical practices (use of
indwelling catheters, etc), changes in the ecology of infective agents, demography of patients at risk or
by prevailing community infections2. Hence to achieve the highest percentage of survival, it is
necessary to determine the pattern of infection in these patients, so that the most effective empiric
therapy maybe used at the earliest sign of infection. In the present paper we retrospectively analyze,
100 positive blood cultures in patients with neutropenia. The data presented here show the similarity in
patterns of infection3 and emerging bacterial resistance at a tertiary referral center in a developing
country.
PATIENTS AND METHODS 
Patients
This study included 100 consecutively bacteremic patients with neutropenia defmed as a neutrophil
count of 0.5x109 /L or less, who developed a sustained temperature of 38 C or above. Patients who
became febrile in proximity to having received blood products were excluded. Patients were included
regardless of whether they had primary neutropenia related to their underlying haematologic
malignancies and were therefore new admissions from the community or they were neutropenic
secondary to cytotoxic therapy while in the hospital.
Microbiologic evaluation
Two sets of blood cultures were obtained. Brain heart infusion broth was used for aerobic cultures and
thioglycolate broth for anaerobic cultures. Cultures were incubated for 7 days. Blind sub- cultures of
medium and gram stains were done daily on blood agar plates and after 48 hours additionallyon
Sabouraud Dextrose Agar for betteryleld of fungus. On the 5th day both anaerobic and aerobic cultures
were plated on chocolate and blood agar plates.
RESULTS 
Analysis of 100 positive blood cultures in neutropenic patients with both haematologic and other
malignancies (Table I)
revealed Pseudomonas aeruginosa as the most common organism. Majority of the patients had
underlying leukemia and remained neutropenic for prolonged time periods. The different types of
organisms and the numbers cultured are shown, in Table II.
Pseudomonas aeruginosa was isolated from 31% of the cases, followed by Staph. aureus in 15%.
Salmonella species isolated in 9% of cases is much higher than reported elsewhere. These isolates have
not been separated according to the type of malignancy or the time of positivity i.e.on admission or
afterwards.
Table III indicates sensitivity patterns of pseudomonas aeruginosa and Staph. aureus. Pseudomonas was
highly (54.8%) resistant to carbenicillin and 9.6% isolates were resistant to gentamycin whereas, 73%
of Staphylococcus aureus were resistant to penicillin and 26% to Erythromycin.
DISCUSSION 
Malignancies, as well as their treatment, are associated with potentially serious and even life-
threatening complications. One of the commonest of these is the development of infections, caused by
a wide variety of pathogenic organisms. Although many reasons exist for the enhanced susceptibility to
infections, neutropenia is the single most important factor. These patients require prompt empiric
antibiotic therapy, if they become febrile, as delay often results in fatality4. Selection of the antibiotic
regimen should take into consideration the organisms that are prevalent in the hospital and their usual
pattern of antibiotic susceptibility. The spectrum of organisms causing infections in neutropenic
patients changes according to the duration of neutropenia5. The concept of empiric antibiotic therapy
was in itiated for febrile leukemic patients in the 1960’s because of the exceptionally high mortality
rate in neutropenic patients if antibiotic administration was delayed until the organism was identified6 .
Since neutropenic patients are unable to mount an adequate inflammatory responses, they are mostly
dependent on antibiotics to control infections. Results of clinical studies have clearly demonstrated that
synergistic antibiotics with high serum bactericidal activity are critical in the management of gram
negative bacillary infections7. There has been a shift in the microbial flora at many oncology centers
during the last 10 years. Increasing number of gram positive organisms specifically Staph. epidermidis,
Staph. aureus, Streptococcus and Bacillus species are being encountered8. However, although these
infections produce moderate morbidity (e.g.fever), mortality is fairly low. Therefore empiric treatment
is mostly directed at the gram-negative organisms. Most clinical studies suggest that empiric therapy
using combinations of two bactericidal antibiotics is necessary9-12. Effective antibiotic combinations
have usually included an aminoglycoside plus an extended spectrum penicillin (e.g. ticarcillin or
carbenicillin) or a broad spectrum antipseudomonal cephalosporin (e.g. ceftazidime, cefotaxime).
Double beta-lactam combinations have also been used but some concern has been expressed that these
combinations may interact in an antagonistic fashion13,14. Inmost studies, however, the double beta-
lactam regimen has been as effective as the beta-lactam plus aminoglycoside15,16. In the patients with
prolonged neutropenia, on multiple antibiotics, the likelihood of fungal infections, e.g., Candida and
Aspergillus increase tremendously17. In these cases empiric amphotericin therapy may have to be
considered. This study demonstrates that in our hospital setting Pseudomonas aeruginosa is the
commonest bacterial isolate, followed by Staph. aureus. We have routinely used cloxacillin and
amikacin as the empiric antibiotic therapy. Besides covering the two most likely organisms, it also
covers against gentamycin-resistant Pseudomonas. In those responding poorly, we add cefotaxime or
azactam to enhance gram negative coverage. Growth of fungus in four patients indicates that it may not
be an uncommon problem in Pakistan and empiric amphotericin therapy is indicated in those who
continue to befebrile and neutropenicwithout any evident infection We conclude that gram negatives
are the commonest bacterial isolates in neutropenic febrile patients, followed by Staph. aureus. Choice
of empiric antibiotic therapy should be tailored towards these organisms. Similar studies need to be
repeated at regular intervals to evaluate any changes in bacteriologic spectrum or their antibiotic sus-
ceptibility.
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